October 8, 2024

Immune Deficiency Foundation Announces New Seed Grant


The Immune Deficiency Foundation (IDF) recently announced the 2024 Research Grant projects that will be supported with a total of $150,000 in funding.

Launched in 2016, IDF’s Research Grant Program supports patient-centred research focused on improving the treatment, health, disease management, or diagnosis of people with primary immunodeficiencies (PIs), also known as inborn errors of immunity (IEI), as well as research that contributes to the general body of PI knowledge.

The four projects selected for 2024 are aimed at reducing the diagnosis time for those with PIs, a core goal of the foundation, and are lead by:

  • Dr. Emily Harris, a clinical fellow in pediatric hematology/oncology at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center – Improving Evans syndrome diagnosis and treatment.
  • Dr. David Nguyen, assistant professor at the University of California, San Francisco – Probing genetic variants in JAK3.
  • Dr. Alexandra Martinson, pediatrics research track resident at Children’s National Hospital in Washington, D.C. – Improving machine learning for PI diagnosis.
  • Dr. Lauren Meyer, pediatric hematology/oncology fellow at Seattle Children’s Hospital – Screening for hemophagocytic lymphohistiocytosis (HLH) with common lab tests.

Learn more about each research project funded for 2024.

Awardees are selected by the IDF’s Research Committee, made up of recognised immunologists and past grant awardees. They review and score research proposals through a peer review process based on the system used by the National Institutes of Health (NIH).

The committee recommends funding proposals with the highest scores, ensuring an unbiased and independent selection process based solely on scientific merit. The Michael Blaese Research Grant Award is given to the highest-scored application each cycle, which, for 2024, was submitted by Dr. Emily Harris for Improving Evans syndrome diagnosis and treatment.

“The inspiring and groundbreaking work of researchers drives important advancements that improve testing and treatment options for the PI community,” said Jorey Berry, President & CEO of the Immune Deficiency Foundation. “While we have a diverse cross-section of grantees for this year, all of the projects are focused on reducing the time to diagnosis. We are grateful for the work of these researchers and their teams in finding new solutions to this important challenge.”